Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have earned a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $17.14.

A number of equities analysts have commented on the stock. UBS Group cut their price target on shares of Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Morgan Stanley reduced their target price on Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Friday, May 10th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Guggenheim upgraded Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Tuesday, May 14th. Finally, Wells Fargo & Company began coverage on Amicus Therapeutics in a report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price objective on the stock.

Insider Activity at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 6,100 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $10.00, for a total transaction of $61,000.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $10.34, for a total value of $77,550.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $9,168,002.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bradley L. Campbell sold 6,100 shares of the stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $10.00, for a total transaction of $61,000.00. Following the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $8,866,540. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Amicus Therapeutics by 5.0% during the fourth quarter. Vanguard Group Inc. now owns 28,492,486 shares of the biopharmaceutical company’s stock valued at $404,308,000 after buying an additional 1,360,613 shares during the period. Perceptive Advisors LLC raised its stake in Amicus Therapeutics by 1.3% in the fourth quarter. Perceptive Advisors LLC now owns 28,057,456 shares of the biopharmaceutical company’s stock worth $398,135,000 after buying an additional 364,539 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Amicus Therapeutics by 101.9% in the fourth quarter. Wellington Management Group LLP now owns 15,190,024 shares of the biopharmaceutical company’s stock worth $215,546,000 after buying an additional 7,666,335 shares during the period. Janus Henderson Group PLC boosted its position in Amicus Therapeutics by 20.1% during the 1st quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock valued at $162,713,000 after acquiring an additional 2,307,385 shares in the last quarter. Finally, William Blair Investment Management LLC boosted its position in Amicus Therapeutics by 12.8% during the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after acquiring an additional 1,477,084 shares in the last quarter.

Amicus Therapeutics Stock Performance

Amicus Therapeutics stock opened at $11.76 on Friday. Amicus Therapeutics has a 1-year low of $9.02 and a 1-year high of $14.57. The company has a current ratio of 3.03, a quick ratio of 2.61 and a debt-to-equity ratio of 2.97. The firm has a market capitalization of $3.48 billion, a PE ratio of -24.00 and a beta of 0.71. The firm’s 50 day simple moving average is $10.49 and its 200 day simple moving average is $11.00.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 34.73% and a negative return on equity of 77.08%. The firm had revenue of $126.67 million during the quarter, compared to analyst estimates of $121.21 million. During the same period in the previous year, the business earned ($0.15) EPS. The business’s revenue for the quarter was up 34.0% on a year-over-year basis. As a group, analysts expect that Amicus Therapeutics will post -0.12 earnings per share for the current fiscal year.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.